Last reviewed · How we verify
Metoclopramide, Granisetron, or Ondansetron
Metoclopramide, Granisetron, or Ondansetron is a Antiemetic agents (dopamine antagonist, 5-HT3 receptor antagonists) Small molecule drug developed by Sanofi. It is currently FDA-approved for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Gastroparesis (metoclopramide).
This is a combination of three distinct antiemetic agents with different mechanisms: metoclopramide blocks dopamine receptors and enhances acetylcholine effects to increase gastric motility, while granisetron and ondansetron are 5-HT3 receptor antagonists that block serotonin signaling in the chemoreceptor trigger zone.
This is a combination of three distinct antiemetic agents with different mechanisms: metoclopramide blocks dopamine receptors and enhances acetylcholine effects to increase gastric motility, while granisetron and ondansetron are 5-HT3 receptor antagonists that block serotonin signaling in the chemoreceptor trigger zone. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Gastroparesis (metoclopramide).
At a glance
| Generic name | Metoclopramide, Granisetron, or Ondansetron |
|---|---|
| Sponsor | Sanofi |
| Drug class | Antiemetic agents (dopamine antagonist, 5-HT3 receptor antagonists) |
| Target | Dopamine receptors (metoclopramide); 5-HT3 receptors (granisetron, ondansetron) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Oncology / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Metoclopramide acts as a dopamine antagonist and acetylcholinesterase inhibitor to promote gastric emptying and reduce nausea at the central and peripheral levels. Granisetron and ondansetron selectively block 5-hydroxytryptamine (serotonin) at 5-HT3 receptors, preventing emetic signals from reaching the vomiting center in the brain. These agents are often used in combination or individually to manage chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Gastroparesis (metoclopramide)
- Migraine-associated nausea (metoclopramide)
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Dizziness
- Tardive dyskinesia (metoclopramide, with long-term use)
Key clinical trials
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NA)
- Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. (PHASE4)
- Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery (PHASE3)
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (PHASE4)
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (PHASE3)
- Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoclopramide, Granisetron, or Ondansetron CI brief — competitive landscape report
- Metoclopramide, Granisetron, or Ondansetron updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Metoclopramide, Granisetron, or Ondansetron
What is Metoclopramide, Granisetron, or Ondansetron?
How does Metoclopramide, Granisetron, or Ondansetron work?
What is Metoclopramide, Granisetron, or Ondansetron used for?
Who makes Metoclopramide, Granisetron, or Ondansetron?
What drug class is Metoclopramide, Granisetron, or Ondansetron in?
What development phase is Metoclopramide, Granisetron, or Ondansetron in?
What are the side effects of Metoclopramide, Granisetron, or Ondansetron?
What does Metoclopramide, Granisetron, or Ondansetron target?
Related
- Drug class: All Antiemetic agents (dopamine antagonist, 5-HT3 receptor antagonists) drugs
- Target: All drugs targeting Dopamine receptors (metoclopramide); 5-HT3 receptors (granisetron, ondansetron)
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Oncology / Anesthesia
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV)
- Indication: Drugs for Postoperative nausea and vomiting (PONV)
- Indication: Drugs for Gastroparesis (metoclopramide)
- Compare: Metoclopramide, Granisetron, or Ondansetron vs similar drugs
- Pricing: Metoclopramide, Granisetron, or Ondansetron cost, discount & access